Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | TAVNEOS | Hidradenitis Suppurativa (severe) | Phase 3 | Oral | Immunology: Anti-TNF | |
| Amgen Inc. | AMG 133 (maridebart cafraglutide) - (MariTide) | Obesity and without diabetes | Phase 2 | Data Released | subcutaneous | Endocrinology |
| Amgen Inc. | Tarlatamab (AMG 757) - (DeLLphi-306) | Limited-stage small cell lung cancer (SCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Amgen Inc. | Tezepelumab - (NAVIGATOR) | Asthma and comorbid nasal polyps | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Amgen Inc. | Bemarituzumab (FPA144) + chemo - (FORTITUDE-101) | Gastric and gastro-esophageal junction cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Amgen Inc. | ADX-914 | Moderate-to-severe atopic dermatitis (AD) | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | LUMAKRAS (Sotorasib) | Non-small cell lung cancer (NSCLC) first line including STK11 mutations | Phase 2 | Oral | Oncology | |
| Amicus Therapeutics Inc. | DMX-200 - (ACTION3) | Focal Segmental Glomerulosclerosis (FSGS) | Phase 3 | Ongoing | Oral | #N/A |
